Chromatin Accessibility Mapping Services
Creative Biolabs delivers comprehensive regulatory maps that bridge the gap between static genomic sequences and dynamic phenotypic execution. By resolving the chromatin landscape, we identify specific "open" genomic regions that dictate oncogenic behavior. Our mapping services provide a definitive view of the regulatory "switches"—such as active enhancers and promoters—within specific tumor models or patient cohorts. This high-resolution approach allows researchers to pinpoint the epigenetic drivers of phenotypic plasticity and therapeutic resistance, transforming raw sequence data into actionable clinical insights.
Background Featured Services What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Epigenetic Frontier in Cancer Research
Cancer is fundamentally driven by epigenetic reprogramming, where phenotypic plasticity enables treatment resistance beyond genetic mutations. Creative Biolabs utilizes chromatin accessibility mapping to identify "open" genomic regions, such as enhancers and promoters, providing a global proxy for regulatory activity. This approach deciphers non-coding mutations in the genome's "dark matter" that create novel oncogenic binding sites. Crucially, we detect minority subpopulations, including rare drug-tolerant persisters, and map regulatory priming. By identifying these primed states before gene expression shifts, we provide a high-resolution window into tumor evolution and future resistance trajectories.
Our Featured Services
ATAC-seq based Chromatin Accessibility Mapping
Creative Biolabs provides high-resolution ATAC-seq mapping to resolve the epigenetic landscape of cancer. We identify "open" regulatory switches and non-coding drivers, delivering actionable data on phenotypic plasticity and therapeutic resistance.
Learn More →
Nucleosome Positioning Analysis
Creative Biolabs provides high-resolution MNase-seq and NOMe-seq to map nucleosome positioning and chromatin accessibility. Our platform resolves occupancy and nucleosomal spacing, identifying critical regulatory regions and epigenetic shifts driving oncogenesis and cellular differentiation.
Learn More →
Key Deliverables and Solutions
Identification of Master Regulators
We utilize high-resolution footprinting to pinpoint the exact transcription factors (TFs) driving oncogenesis. Unlike simple mRNA expression data, our mapping reveals which TFs are physically engaged with the DNA, providing a more accurate reflection of active regulatory networks.
Discovery of Distal Enhancer Elements
A significant portion of cancer-driving alterations occurs in the "dark matter" of the genome. Our services prioritize the discovery of distal enhancers, which exhibit higher cancer-type specificity than promoters, offering superior targets for precision medicine and diagnostic stratification.
Resolution of Minority Subpopulations
Utilizing single-molecule and single-cell resolution, we can detect "primed" epigenetic states in rare cell populations. This is critical for identifying drug-tolerant persisters that often evade detection in bulk assays but eventually drive clinical recurrence.
Discover How We Can Help - Request a Consultation to Discuss Your Regulatory Mapping Needs
Workflow
Our workflow is engineered for maximum biological signal recovery and technical reproducibility, ensuring that even the most limited specimens yield high-quality data.
Publication
This study presents a large-scale, single-cell multi-omic atlas of chromatin accessibility and gene expression across 11 cancer types. By analyzing over one million cells, it maps epigenetic drivers—such as regulatory elements and transcription factors—associated with tumor initiation, progression, and metastasis. The work reveals both pan-cancer and cancer-specific epigenetic programs, demonstrates cooperation between epigenetic and genetic alterations, and provides a foundational resource for understanding the dynamic epigenetic landscape of cancer evolution.
Fig.1 Chromatin accessibility landscapes in 11 human cancer types. 1
Why Choose Us?
Creative Biolabs leads the epigenomic revolution by merging traditional accessibility assays with spatial and single-molecule resolution. We utilize validated pipelines to identify clinical-grade biomarkers in the non-coding genome, rapidly transitioning findings into therapeutic leads. Our protocols are optimized for low-input clinical biopsies and frozen tissues, ensuring high-resolution data from archival materials. As a pioneer in "tri-omic" profiling, we simultaneously analyze protein data. This multi-modal approach enables the complete reconstruction of the tumor microenvironment's molecular architecture, bridging the gap between epigenetic states and functional phenotypic execution.
Experience the Creative Biolabs Advantage - Get a Personalized Quote Today
FAQs
How does your service distinguish between open chromatin and DNA damage?
We use rigorous QC metrics, including fragment size distribution analysis, to ensure that the signal originates from nucleosomal periodicity rather than random DNA fragmentation.
Can your services detect rare cell populations in a heterogeneous tumor?
Yes. Our ATAC-seq platform is specifically designed to isolate and profile the regulatory landscape of rare subpopulations, such as cancer stem cells or infiltrating immune cells.
What is the benefit of mapping distal enhancers over promoters?
Distal enhancers are more tissue- and cancer-specific than promoters. Mapping them provides a more precise signature for patient stratification and identifying cell-state-specific vulnerabilities.
Customer Review
-
Unprecedented Resolution for Drug Persistence
Utilizing Creative Biolabs' specialized mapping in our neuro-oncology research significantly facilitated the identification of drug-tolerant persister cells. The TF footprinting data provided a level of clarity that bulk RNA-seq simply couldn't offer. – Dr. A*n S
-
Seamless Multi-omic Workflow
The integrative ATAC + RNA analysis provided a truly holistic view of our immunotherapy models. The peak-to-gene linkage reports saved our internal team months of bioinformatic correlation work. – Dr. J*ne K
Related Services
To achieve a complete understanding of the cancer epigenome, Creative Biolabs recommends integrating chromatin accessibility mapping with the following complementary services:
Microarray-based Tumor Profiling
Creative Biolabs provides high-throughput microarray-based tumor profiling for SNP, DNA methylation, mRNA, and miRNA analysis. We deliver rapid, affordable data on cancer subcategories and prognosis to advance personalized research.
Learn More →
RNA Modification Tumor Cellular Metabolism Assay
Creative Biolabs provides comprehensive RNA modification analysis (m6A, m5C, m1A) to monitor tumor microenvironment shifts. We detect transcriptomic biomarkers to identify drivers of proliferation and drug resistance.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs provides the most advanced chromatin accessibility mapping services available to the scientific community. From resolving intratumoral heterogeneity to predicting drug resistance through "regulatory priming," we provide the high-resolution data and expert analysis required to drive oncology programs forward.
Partner with Creative Biolabs today to illuminate the regulatory drivers of your cancer models.
Reference
-
Terekhanova, Nadezhda V., et al. "Epigenetic regulation during cancer transitions across 11 tumour types." Nature 623.7986 (2023): 432-441. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41586-023-06682-5
For Research Use Only | Not For Clinical Use
Download our brochure